Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

Anna Borodovsky, PhD, Kristina Yucius, Andrew Sprague, Nirmal K Banda, PhD, V. Michael Holers, MD, Akshay Vaishnaw, MD PhD, Martin Maier, PhD, Rajeev Kallanthottathil, PhD, Klaus Charisse, PhD, Satya Kuchimanchi, PhD, Muthiah Manoharan, PhD, David J Salant, MD, Kevin Fitzgerald, PhD, Rachel Meyers, PhD, Benny Sorensen, MD PhD

Blood (2014) 124 (21): 1606.

https://doi.org/10.1182/blood.V124.21.1606.1606

Published: 2014

Journal Articles

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Spero R. Cataland, V. Michael Holers, Susan Geyer, Shangbin Yang, Haifeng M. Wu

Blood (2014) 123 (24): 3733–3738.

https://doi.org/10.1182/blood-2013-12-547067

Published: 2014

Includes: Supplemental data

Journal Articles

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

Spero R Cataland, M.D., V. Michael Holers, M.D., Shangbin Yang, Ph.D., Haifeng M Wu, M.D.

Blood (2013) 122 (21): 3552.

https://doi.org/10.1182/blood.V122.21.3552.3552

Published: 2013

Journal Articles

Complement Activation in Patients with Acquired Thrombotic Thrombocytopenic Pupura (TTP)

Shangbin Yang, Spero R Cataland, M.D., V. Michael Holers, M.D., Ante S Lundberg, M.D., Haifeng Wu, M.D.

Blood (2012) 120 (21): 3323.

https://doi.org/10.1182/blood.V120.21.3323.3323

Published: 2012

Journal Articles

Mortality From Thrombotic Thrombocytopenic Purpura Is Related to Complement Hyperactivation

Trudy C. Wu, Shangbin Yang, Sara Haven, V. Michael Holers, M.D., Ante S. Lundberg, M.D., Haifeng Wu, M.D., Spero R. Cataland, M.D.

Blood (2012) 120 (21): 488.

https://doi.org/10.1182/blood.V120.21.488.488

Published: 2012

Journal Articles

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, Michela Sica, Luigi del Vecchio, Christopher J. Horvath, Masha Fridkis-Hareli, Carmine Selleri, Margaret A. Lindorfer, Ronald P. Taylor, Lucio Luzzatto, V. Michael Holers

Blood (2012) 119 (26): 6307–6316.

https://doi.org/10.1182/blood-2011-12-398792

Published: 2012

Includes: Supplemental data

Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers

Blood (2011) 118 (17): 4705–4713.

https://doi.org/10.1182/blood-2011-06-359646

Published: 2011

Includes: Supplemental data

Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD

Blood (2010) 116 (21): 637.

https://doi.org/10.1182/blood.V116.21.637.637

Published: 2010

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

Antonio M. Risitano, MD, PhD, V. Michael Holers, Bruno Rotoli

Blood (2009) 114 (22): 158.

https://doi.org/10.1182/blood.V114.22.158.158

Published: 2009

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

NARROW

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

Complement Activation in Patients with Acquired Thrombotic Thrombocytopenic Pupura (TTP)

Mortality From Thrombotic Thrombocytopenic Purpura Is Related to Complement Hyperactivation

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only